Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

3.715 -0.085 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Athira Pharma Inc

< Previous 1 2 3 4 5 6 Next >
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via Globe NewsWire
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA). 
Via SBWire
Athira Pharma Provides 2023 Pipeline Outlook
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models 
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases 
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS 
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration 
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present at Stifel 2022 Healthcare Conference
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy 
From Athira Pharma, Inc.
Via Globe NewsWire
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
From Athira Pharma, Inc.
Via Globe NewsWire
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:ATHA Long Term Investor Notice: Investigation of Potential Wrongdoing at Athira Pharma, Inc.
San Diego, CA -- (SBWIRE) -- 10/01/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Athira Pharma, Inc. 
Via SBWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ATHIRA SHAREHOLDER NOTICE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ATHIRA SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ATHIRA DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
CLASS ACTION UPDATE for ATHA, OTLY and AHCO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 24, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ATHIRA DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors – ATHA
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
CLASS ACTION UPDATE for ATHA, CRMD and VIEW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 23, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.